Resultados globales: 1 registros encontrados en 0.01 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
10 p, 809.5 KB The MUK five protocol : a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma / Brown, Sarah (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Hinsley, Samantha (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Ballesteros Silva, Mónica Patricia (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ; Bourne, Sue (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; McGarry, Paul (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Sherratt, Debbie (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Flanagan, Louise (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Gregory, Walter (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ; Cavenagh, Jamie (St Bartholomew's Hospital (Regne Unit)) ; Owen, Roger (HMDS Laboratory, St James's University Hospital, Leeds, UK) ; Williams, Cathy (Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK) ; Kaiser, Martin (The Institute of Cancer Research, Sutton, UK) ; Low, Eric (Myeloma UK, Edinburgh, UK) ; Yong, Kwee (UCL Cancer Institute (Londres, Regne Unit))
Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately 40-50 per million i. e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib (Velcade®) and dexamethasone (CVD) is an effective regimen at relapse and has emerged in recent years as the standard therapy at first relapse in the UK. [...]
2016 - 10.1186/s12878-016-0053-9
BMC Hematology, Vol. 16 (may 2016)  

Vea también: autores con nombres similares
2 Williams, C.
1 Williams, C.Y.
1 Williams, Charles
1 Williams, Chris
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.